NeuroFrontiers
by ReachMD
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 2 chart positions in 2 markets.
By chart position
- 🇸🇦SA · Science#130500 to 3K
- 🇵🇭PH · Science#140500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
500 to 3K🎙 ~2x weekly·179 episodes·Last published 2mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
1K to 6K🇸🇦50%🇵🇭50% - Active Followers
Loyal subscribers who consistently listen
300 to 1.8K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 12 epsHosts
Recent guests
Recent episodes
Advancing MOGAD Care
Jun 24, 2026
10m 04s
Multidisciplinary Coordination in TK2d Diagnosis and Management
Jun 24, 2026
11m 15s
Navigating Stem Cell Therapy Conversations in MS
Jun 8, 2026
4m 45s
Cognitive Screening in MS: Practical Strategies and Modern Approaches
May 28, 2026
3m 30s
Identifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role
May 14, 2026
14m 45s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/24/26 | MOGADneurology+3 | Michael Levy, MD, PhDPeter V. Sguigna, MD | Massachusetts General HospitalUT Southwestern Medical Center | — | MOGADmyelin oligodendrocyte glycoprotein+4 | — | 10m 04s | ||
| 6/24/26 | TK2dmultidisciplinary care+4 | Zarazuela Zolkipli-CunninghamOscar H. (Hank) Mayer | Children's Hospital of Philadelphia | — | TK2dthymidine kinase 2 deficiency+4 | — | 11m 15s | ||
| 6/8/26 | stem cell therapymultiple sclerosis+3 | Jaime Imitola, MDJaime Imitola | UConn Health | multiple sclerosis | stem cell therapymultiple sclerosis+3 | — | 4m 45s | ||
| 5/28/26 | cognitive screeningmultiple sclerosis+3 | Elizabeth S. Gromisch, PhDElizabeth S. Gromisch | Joyce D. and Andrew J. Mandell Center for Comprehensive Multiple Sclerosis Care and Neuroscience ResearchMount Sinai Rehabilitation Hospital+1 | — | cognitive changesscreening tools+3 | — | 3m 30s | ||
| 5/14/26 | respiratory symptomspulmonologist role+3 | Bethany Lussier | UT Southwestern Medical CenterDivision of Pulmonary and Critical Care Medicine | — | TK2drespiratory manifestations+3 | — | 14m 45s | ||
| 5/14/26 | thymidine kinase 2 deficiencyneuromuscular disorders+3 | Kaitlin Batley | Children’s HealthUT Southwestern Medical Center | — | TK2dfatigue+5 | — | 13m 30s | ||
| 5/1/26 | Myasthenia Gravistreatment variability+3 | Henry Kaminski, MDHenry Kaminski | The George Washington University School of Medicine and Health Sciences | — | Myasthenia Gravistreatment variability+3 | — | 3m 45s | ||
| 4/30/26 | genetic prevalencethymidine kinase 2 deficiency+3 | Austin Larson, MD | University of Colorado Anschutz | — | TK2dthymidine kinase 2 deficiency+3 | — | 14m 01s | ||
| 3/30/26 | multiple sclerosisMcDonald criteria+5 | Aaron Miller, MDAaron Miller | Corinne Goldsmith Dickinson Center for Multiple SclerosisIcahn School of Medicine at Mount Sinai | — | multiple sclerosisMcDonald criteria+5 | — | 3m 00s | ||
| 2/19/26 | multiple sclerosisaging signatures+3 | Adil Harroud, MDDylan Hamitouche+1 | Montreal Neurological InstituteMcGill University | — | multiple sclerosisaging signatures+3 | — | 10m 45s | ||
| 2/19/26 | pediatric multiple sclerosisbiological aging+3 | Jennifer Yang, MDJennifer Yang | UC San Diego School of MedicineRady Children's Hospital | — | multiple sclerosispediatric neurology+3 | — | 5m 15s | ||
| 2/19/26 | multiplex proteomic biomarkersmultiple sclerosis+4 | Raphael Schneider, MD, PhD, FRCPC, CIPRaphael Schneider | BARLO MS CentreSt. Michael’s Hospital+1 | — | multiplex proteomic biomarkersmultiple sclerosis+4 | — | 5m 15s |
Showing 12 of 12
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart history for NeuroFrontiers
Peaked at #130 in SA, currently #130 in SA.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| SA | — | #130 | #130 | — |
| PH | — | #140 | #140 | — |
Chart Positions
2 placements across 2 markets.
Chart Positions
2 placements across 2 markets.